Market Cap 129.95M
Revenue (ttm) 2.82M
Net Income (ttm) -127.50M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,521.28%
Debt to Equity Ratio 0.18
Volume 326,800
Avg Vol 442,672
Day's Range N/A - N/A
Shares Out 56.75M
Stochastic %K 48%
Beta 0.99
Analysts Strong Sell
Price Target $8.57

Company Profile

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) is in Phase I clinical trial, as...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 399 9500
Address:
830 Winter Street, Waltham, United States
DanishViking92
DanishViking92 Oct. 24 at 3:17 PM
$TCRX Update Monday and trading in $2.2s cmon!? Update from management on Monday, should be at +$3 already.. guess we can thank the Ukraine catastrophy for that, please just surrender at get over with it, you are going to lose territory anyway its just a matter of when and everyday until then cost everyone a hell lot of money and people are dying until it ends.
0 · Reply
Orlandotrader
Orlandotrader Oct. 23 at 12:28 AM
$TCRX Data incoming!!!!Monday October 27 Presentations.
0 · Reply
Orlandotrader
Orlandotrader Oct. 23 at 12:27 AM
$TCRX We are excited to present our initial findings at the upcoming ACR Convergence. Among other discoveries, we believe we have identified several shared T-cell targets in Ankylosing Spondylitis. Therapeutic targets for AS have remained elusive despite decades of research and these recent novel discoveries, which are critical to advancing the next generation of therapeutics for autoimmune disorders, highlight the power of our TargetScan technology.” Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease Session Date/Time: Monday, October 27; 10:00 - 11:30 a.m. Central Time Presentation Time: 10:45 - 11:00 a.m. Central Time Location: Poster Hall
0 · Reply
leis5
leis5 Oct. 22 at 2:29 PM
$TCRX why down?
0 · Reply
Deliver1
Deliver1 Oct. 22 at 12:59 AM
$TCRX Review of current analysts: https://www.tipranks.com/stocks/tcrx/forecast
0 · Reply
Dirk1969
Dirk1969 Oct. 19 at 11:07 AM
$TCRX $GOOGL Why does Alphabet have a stake in this company?
2 · Reply
DanishViking92
DanishViking92 Oct. 17 at 9:21 AM
$SKYE come over to $TCRX before it hits $6.. it went from $2 to $2.50 in last couple of days. 2 year results coming soon! New type of cancer treatment, where you use the persons own immune system to eliminate the t-cells!
0 · Reply
Deliver1
Deliver1 Oct. 17 at 12:48 AM
$TCRX $TCRX Is TSCAN participating in ASH 2025? https://www.hematology.org/meetings/annual-meeting That would be the time and place for an update on the ALOHA trial and announcement of the registration trial, imo. Of course sooner is acceptable as well! So far i haven't heard anything.
1 · Reply
Deliver1
Deliver1 Oct. 17 at 12:43 AM
$TCRX Is TSCAN participating in ASH 2025? https://www.hematology.org/meetings/annual-meeting That would be the time and place for an update on the ALOHA trial and announcement of the registration trial, imo. Of course sooner is acceptable as well!
0 · Reply
DanishViking92
DanishViking92 Oct. 17 at 12:12 AM
0 · Reply
Latest News on TCRX
TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025

Mar 7, 2025, 11:31 AM EST - 8 months ago

TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025


TScan Therapeutics Announces Closing of Upsized Public Offering

Apr 19, 2024, 10:05 AM EDT - 1 year ago

TScan Therapeutics Announces Closing of Upsized Public Offering


DanishViking92
DanishViking92 Oct. 24 at 3:17 PM
$TCRX Update Monday and trading in $2.2s cmon!? Update from management on Monday, should be at +$3 already.. guess we can thank the Ukraine catastrophy for that, please just surrender at get over with it, you are going to lose territory anyway its just a matter of when and everyday until then cost everyone a hell lot of money and people are dying until it ends.
0 · Reply
Orlandotrader
Orlandotrader Oct. 23 at 12:28 AM
$TCRX Data incoming!!!!Monday October 27 Presentations.
0 · Reply
Orlandotrader
Orlandotrader Oct. 23 at 12:27 AM
$TCRX We are excited to present our initial findings at the upcoming ACR Convergence. Among other discoveries, we believe we have identified several shared T-cell targets in Ankylosing Spondylitis. Therapeutic targets for AS have remained elusive despite decades of research and these recent novel discoveries, which are critical to advancing the next generation of therapeutics for autoimmune disorders, highlight the power of our TargetScan technology.” Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease Session Date/Time: Monday, October 27; 10:00 - 11:30 a.m. Central Time Presentation Time: 10:45 - 11:00 a.m. Central Time Location: Poster Hall
0 · Reply
leis5
leis5 Oct. 22 at 2:29 PM
$TCRX why down?
0 · Reply
Deliver1
Deliver1 Oct. 22 at 12:59 AM
$TCRX Review of current analysts: https://www.tipranks.com/stocks/tcrx/forecast
0 · Reply
Dirk1969
Dirk1969 Oct. 19 at 11:07 AM
$TCRX $GOOGL Why does Alphabet have a stake in this company?
2 · Reply
DanishViking92
DanishViking92 Oct. 17 at 9:21 AM
$SKYE come over to $TCRX before it hits $6.. it went from $2 to $2.50 in last couple of days. 2 year results coming soon! New type of cancer treatment, where you use the persons own immune system to eliminate the t-cells!
0 · Reply
Deliver1
Deliver1 Oct. 17 at 12:48 AM
$TCRX $TCRX Is TSCAN participating in ASH 2025? https://www.hematology.org/meetings/annual-meeting That would be the time and place for an update on the ALOHA trial and announcement of the registration trial, imo. Of course sooner is acceptable as well! So far i haven't heard anything.
1 · Reply
Deliver1
Deliver1 Oct. 17 at 12:43 AM
$TCRX Is TSCAN participating in ASH 2025? https://www.hematology.org/meetings/annual-meeting That would be the time and place for an update on the ALOHA trial and announcement of the registration trial, imo. Of course sooner is acceptable as well!
0 · Reply
DanishViking92
DanishViking92 Oct. 17 at 12:12 AM
0 · Reply
Orlandotrader
Orlandotrader Oct. 16 at 7:43 PM
$TCRX Found this one late but Started 1000 today. Will add on Dips back to 2$ . Data incoming.
0 · Reply
leis5
leis5 Oct. 16 at 5:59 PM
$TCRX https://finance.yahoo.com/news/2-overlooked-stocks-snap-2025-113002307.html
0 · Reply
DanishViking92
DanishViking92 Oct. 13 at 2:02 PM
$TCRX Once we finally get some positive news from the management =
0 · Reply
Btolz
Btolz Oct. 10 at 12:19 AM
$TCRX this will do the same thing tomorrow
0 · Reply
GeorgeJonesFan_In_Boston
GeorgeJonesFan_In_Boston Oct. 9 at 8:26 PM
$TCRX up 85% in past 6 months
0 · Reply
DanishViking92
DanishViking92 Oct. 9 at 7:29 PM
$TCRX 1.5m volume today.. i bet someone knows something and are loading up before this takes off for real!
1 · Reply
vu_jade
vu_jade Oct. 9 at 5:28 PM
$TCRX added 2.11
0 · Reply
Btolz
Btolz Oct. 9 at 4:04 PM
$TCRX Just keep climbing up
0 · Reply
DanishViking92
DanishViking92 Oct. 8 at 1:38 PM
$TCRX $6 before 2026 - lets goo!
1 · Reply
SPYmyQQQ
SPYmyQQQ Oct. 7 at 9:03 PM
🚀 New Signal ✅ 💊 $TCRX 🗓️ Oct 7, 2025 💵 Entry: $1.96 🎯 Target (Opt.): $2.35 (+19.90%) 👉 FREE TRIAL! Check bio.
0 · Reply
DanishViking92
DanishViking92 Oct. 7 at 3:41 PM
0 · Reply
14kmaker
14kmaker Oct. 2 at 10:50 AM
$TCRX Checkpoint Capital L.P. raised its holdings in TScan Therapeutics by 14.9%, now owning 2,017,650 shares valued at approximately $2.78 million, making it the firm's 10th largest investment. Institutional ownership is significant, with 82.83% of TScan Therapeutics shares held by institutions and hedge funds, indicating strong support from large investors. Analysts have mixed outlooks on the stock, with a consensus rating of "Buy" and a price target range from $7.00 to $10.00, suggesting potential upside despite recent market volatility.
1 · Reply